Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non‐gemfibrozil fibrate trials
Journal of Internal Medicine · 2024
DOI: 10.1111/joim.13771 ↗Kurz gefasst
Leserbrief in der Zeitschrift Journal of Internal Medicine, 2024. Verfasst von Takahito Doi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark. Hauptthemen laut MEDLINE: Gemfibrozil, Cholesterol. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 10 Literaturangaben. Gefördert von: Region Hovedstaden, Japan Society for Science Promotion Postdoctral Fellowship for Research Abroad.
Abstract (Originalsprache)
Table S1. Absolute changes of lipid traits in PROMINENT, ACCORD, FIELD, BIP, VA-HIT, and HHS. Table S2. Comparison of different gemfibrozil and non-gemfibrozil fibrate trials and CGPS mimicking corresponding trial. Figure S1. Comparison of gemfibrozil and non-gemfibrozil fibrate trials and corresponding Copenhagen General Population Study mimicking trials using calculated LDL cholesterol and remnant cholesterol by the Martin-Hopkins equation. Figure S2. Comparison of gemfibrozil and non-gemfibrozil fibrate trials and corresponding Copenhagen General Population Study mimicking trials using non-HDL cholesterol. Please note: The publisher is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Biochemistry, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark.
- The Copenhagen General Population Study, Copenhagen University Hospital, Herlev and Gentofte, Herlev, Denmark.
- Faculty of Health and Medical Sciences, Institute of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
ORCID-Profile: Anne Langsted, Børge G Nordestgaard
Förderung
- Region Hovedstaden
- Japan Society for Science Promotion Postdoctral Fellowship for Research Abroad
Zitieren
APA
Doi, T., Langsted, A., & Nordestgaard, B. G. (2024). Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non‐gemfibrozil fibrate trials. Journal of Internal Medicine. https://doi.org/10.1111/joim.13771
Vancouver
Doi T, Langsted A, Nordestgaard BG. Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non‐gemfibrozil fibrate trials. Journal of Internal Medicine. 2024. doi:10.1111/joim.13771
BibTeX
@article{Doi2024,
author = {Doi, Takahito and Langsted, Anne and Nordestgaard, Børge G},
title = {Mass changes in remnant cholesterol and LDL cholesterol explain part of the results of gemfibrozil and non‐gemfibrozil fibrate trials},
journal = {Journal of Internal Medicine},
year = {2024},
doi = {10.1111/joim.13771}
}
EUVIMED